J Korean Neurosurg Soc.  2019 May;62(3):296-301. 10.3340/jkns.2019.0099.

Antiepileptic Drugs in Children: Current Concept

• Lee J

• KMID: 2453234
• DOI: http://doi.org/10.3340/jkns.2019.0099

Abstract

An epileptic seizure is defined as the transient occurrence of signs and/or symptoms due to abnormally excessive or synchronous neuronal activity in the brain. The type of seizure is defined by the mode of onset and termination, clinical manifestation, and by the abnormal enhanced synchrony. If seizures recur, that state is defined as epilepsy. Antiepileptic drugs (AEDs) are the mainstay of treatment. Knowledge about initiating and maintaining adequate AEDs is beneficial for the clinician who treats children with epilepsy. This article will delineate the general principles for selecting, introducing, and discontinuing AEDs and outline guidelines for monitoring adverse effects. In general, AED therapy following a first unprovoked seizure in children is not recommended. However, treatment should be considered after a second seizure. In children and adolescents, if they are seizure-free for at least 2 years, attempts to withdraw medication/s should be made, taking into account the risks vs. benefits for the individual patient. The decision on when and what AED to use should be tailored according to the patient. For optimal treatment, the selection of adequate AEDs can be achieved by considering the precise definition of the patient's seizure and epilepsy syndrome. Continuous monitoring of both therapeutic and adverse effects is critical for successful treatment with AEDs.

Keyword

Seizures; Epilepsy; Antiepileptic drug; Child; Adolescent; Adverse effect

MeSH Terms

Adolescent
Anticonvulsants*
Brain
Child*
Epilepsy
Humans
Neurons
Seizures
Anticonvulsants

Figure

• 

  Fig. 1. Steps for selection of adequate AEDs in children with epilepsy. ACTH : adrenocorticotropic hormone, AED : antiepileptic drug.

Reference

References

1. Aldenkamp AP, Alpherts WC, Sandstedt T, Blennow G, Elmqvist G, Heijbel J, et al. Antiepileptic drug-related cognitive complaints in seizurefree children with epilepsy before and after drug discontinuation. Epilepsia. 39:1070–1074. 1998.

2. Ambrosetto G, Tassinari CA. Antiepileptic drug treatment of benign childhood epilepsy with rolandic spikes: is it necessary? Epilepsia. 31:802–805. 1990.

3. Andersson T, Braathen G, Persson A, Theorell K. A comparison between one and three years of treatment in uncomplicated childhood epilepsy: a prospective study. II. The EEG as predictor of outcome after withdrawal of treatment. Epilepsia. 38:225–232. 1997.

4. Beghi E, Giussani G, Grosso S, Iudice A, La Neve A, Pisani F, et al. Withdrawal of antiepileptic drugs: guidelines of the Italian League Against Epilepsy. Epilepsia 54 Suppl. 7:2–12. 2013.

5. Berg AT, Shinnar S. Relapse following discontinuation of antiepileptic drugs: a meta-analysis. Neurology. 44:601–608. 1994.

6. Berg AT, Shinnar S, Levy SR, Testa FM, Smith-Rapaport S, Beckerman B, et al. Two-year remission and subsequent relapse in children with newly diagnosed epilepsy. Epilepsia. 42:1553–1562. 2001.

7. Blumer D, Montouris G, Hermann B. Psychiatric morbidity in seizure patients on a neurodiagnostic monitoring unit. J Neuropsychiatry Clin Neurosci. 7:445–456. 1995.

8. Braathen G, Andersson T, Gylje H, Melander H, Naglo AS, Norén L, et al. Comparison between one and three years of treatment in uncomplicated childhood epilepsy: a prospective study. I. Outcome in different seizure types. Epilepsia. 37:822–832. 1996.

9. Chong DJ, Bazil CW. Update on anticonvulsant drugs. Curr Neurol Neurosci Rep. 10:308–318. 2010.

10. Chong DJ, Lerman AM. Practice update: review of anticonvulsant therapy. Curr Neurol Neurosci Rep. 16:39. 2016.

11. Commission on Epidemiology and Prognosis; International League Against Epilepsy. Guidelines for epidemiologic studies on epilepsy. Commission on Epidemiology and Prognosis, International League Against Epilepsy. Epilepsia. 34:592–596. 1993.

12. Delgado MR, Riela AR, Mills J, Pitt A, Browne R. Discontinuation of antiepileptic drug treatment after two seizure-free years in children with cerebral palsy. Pediatrics. 97:192–197. 1996.

13. Dooley J, Gordon K, Camfield P, Camfield C, Smith E. Discontinuation of anticonvulsant therapy in children free of seizures for 1 year: a prospective study. Neurology. 46:969–974. 1996.

14. Fégueux S, De Truchis P, Balloul H, Maslo C, Matheron S, Coulaud JP. Sulphadiazine desensitization in AIDS patients. AIDS. 5:1275–1276. 1991.

15. Fisher RS, Acevedo C, Arzimanoglou A, Bogacz A, Cross JH, Elger CE, et al. ILAE official report: a practical clinical definition of epilepsy. Epilepsia. 55:475–482. 2014.

16. Fisher RS, van Emde Boas W, Blume W, Elger C, Genton P, Lee P, et al. Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia. 46:470–472. 2005.

17. Freeman JM, Tibbles J, Camfield C, Camfield P. Benign epilepsy of childhood: a speculation and its ramifications. Pediatrics. 79:864–868. 1987.

18. Halma E, de Louw AJ, Klinkenberg S, Aldenkamp AP, DM IJ, Majoie M. Behavioral side-effects of levetiracetam in children with epilepsy: a systematic review. Seizure. 23:685–691. 2014.

19. Hirsch LJ, Arif H, Nahm EA, Buchsbaum R, Resor SR Jr, Bazil CW. Crosssensitivity of skin rashes with antiepileptic drug use. Neurology. 71:1527–1534. 2008.

20. Hirtz D, Berg A, Bettis D, Camfield C, Camfield P, Crumrine P, et al. Practice parameter: treatment of the child with a first unprovoked seizure: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology. 60:166–175. 2003.

21. Holowach J, Thurston DL, O’Leary J. Prognosis in childhood epilepsy. Follow-up study of 148 cases in which therapy had been suspended after prolonged anticonvulsant control. N Engl J Med. 286:169–174. 1972.

22. Jacoby A, Johnson A, Chadwick D. Psychosocial outcomes of antiepileptic drug discontinuation. The Medical Research Council AED Withdrawal Study Group. Epilepsia. 33:1123–1131. 1992.

23. Kanner AM, Balabanov A. Depression and epilepsy: how closely related are they? Neurology. 58(8 Suppl 5):S27–S39. 2002.

24. Klassen BD, Sadler RM. Induction of hypersensitivity to a previously tolerated antiepileptic drug by a second antiepileptic drug. Epilepsia. 42:433–435. 2001.

25. Kuyucu S, Caubet JC. Hypersensitivity reactions to antiepileptic drugs in children: epidemiologic, pathogenetic, clinical, and diagnostic aspects. J Allergy Clin Immunol Pract. 6:1879–1891. e1. 2018.

26. Lee J, Park EG, Lee M, Lee J. Desensitization to oxcarbazepine: longterm efficacy and tolerability. J Clin Neurol. 13:47–54. 2017.

27. Mehta M, Shah J, Khakhkhar T, Shah R, Hemavathi KG. Anticonvulsant hypersensitivity syndrome associated with carbamazepine administration: case series. J Pharmacol Pharmacother. 5:59–62. 2014.

28. Panayiotopoulos CP, Obeid T, Tahan AR. Juvenile myoclonic epilepsy: a 5-year prospective study. Epilepsia. 35:285–296. 1994.

29. Patsalos PN, Berry DJ, Bourgeois BF, Cloyd JC, Glauser TA, Johannessen SI, et al. Antiepileptic drugs--best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia. 49:1239–1276. 2008.

30. Schmitz EB, Moriarty J, Costa DC, Ring HA, Ell PJ, Trimble MR. Psychiatric profiles and patterns of cerebral blood flow in focal epilepsy: interactions between depression, obsessionality, and perfusion related to the laterality of the epilepsy. J Neurol Neurosurg Psychiatry 6. 2:458–463. 1997.

31. Shinnar S, Berg AT. Does antiepileptic drug therapy prevent the development of “chronic” epilepsy? Epilepsia. 37:701–708. 1996.

32. Shinnar S, Berg AT, Moshé SL, Kang H, O’Dell C, Alemany M, et al. Discontinuing antiepileptic drugs in children with epilepsy: a prospective study. Ann Neurol. 35:534–545. 1994.

33. Shinnar S, Berg AT, O’Dell C, Newstein D, Moshe SL, Hauser WA. Predictors of multiple seizures in a cohort of children prospectively followed from the time of their first unprovoked seizure. Ann Neurol. 48:140–147. 2000.

34. Shinnar S, Vining EP, Mellits ED, D’Souza BJ, Holden K, Baumgardner RA, et al. Discontinuing antiepileptic medication in children with epilepsy after two years without seizures. A prospective study. N Engl J Med. 313:976–980. 1985.

35. Sillanpää M, Jalava M, Kaleva O, Shinnar S. Long-term prognosis of seizures with onset in childhood. N Engl J Med. 338:1715–1722. 1998.

36. Stroink H, Brouwer OF, Arts WF, Geerts AT, Peters AC, van Donselaar CA. The first unprovoked, untreated seizure in childhood: a hospital based study of the accuracy of the diagnosis, rate of recurrence, and long term outcome after recurrence. Dutch study of epilepsy in childhood. J Neurol Neurosurg Psychiatry. 64:595–600. 1998.

37. Verrotti A, Morresi S, Basciani F, Cutarella R, Morgese G, Chiarelli F. Discontinuation of anticonvulsant therapy in children with partial epilepsy. Neurology. 55:1393–1395. 2000.

38. Vining EPG, Mellitis ED, Dorsen MM, Cataldo MF, Quaskey SA, Spielberg SP, et al. Psychologic and behavioral effects of AEDs in children: a double-blind comparison between phenobarbital and valproic acid. Pediatrics. 80:165–174. 1987.